Biochimica et Biophysica Acta (BBA) - General Subjects
IgG glycan patterns are associated with type 2 diabetes in independent European populations
Introduction
Type 2 diabetes is an extremely challenging health issue in the 21st century [1]. It is a multifactorial disease, resulting from intricate interplay between environmental and genetic factors. Although many environmental and genetic risk factors have been identified, the underlying mechanisms of the disease remain largely unknown.
Genetic factors identified so far explain up to 5–10% of disease risk [2]. It is likely that epigenetic and posttranscriptional modifications play a substantial role in disease pathophysiology. Glycosylation of proteins is one of the most common posttranslational modifications. N-glycans are present on most proteins and are generated through interplays between hundreds of enzymes [3], [4]. They play structural, functional, and regulatory roles and reflect genetic, metabolic, and environmental factors [3]. These unique qualities raise interest for the role and use of N-glycans in complex disease such as type 2 diabetes. Total N-glycomic changes have been reported once in a relatively large type 2 diabetes population and showed significant changes. However, total N-glycomic changes do not inform us on the exact underlying proteins and processes involved and results are influenced by the relative abundance of proteins in the circulation.
Type 2 diabetes is characterized by a pro-inflammatory state and elevated levels of inflammatory markers, such as C-reactive protein and interleukin-6, that have been associated with risk of developing type 2 diabetes [5]. IgG N-glycome changes have been linked to clinical risk factors for type 2 diabetes, such as age, BMI, smoking, and dyslipidemia [6], [7], [8], [9]. IgG is a tetramer protein complex consisting of Fc and Fab regions. IgG glycosylation is particularly interesting, as N-glycans attached to the Fc part of IgG can modulate and switch its function from pro- to anti-inflammatory and vice versa [3], [10], [11]. However, IgG N-glycosylation patterns in type 2 diabetes compared to the non-diabetic state have not been described in current literature. Knowledge on specific IgG N-glycosylation profiles in type 2 diabetes could shed light on underlying inflammatory pathophysiological processes and on drug target and biomarker potential.
We hypothesized that characteristic IgG N-glycan profiles are present in type 2 diabetes. In this study, we investigated the association of IgG N-glycan profiles with type 2 diabetes in a large population-based case control cohort, followed by replication in independent European samples. Moreover, we evaluate the AUC under the Receiver Operator Characteristic (ROC) curves for models including clinical characteristics, IgG glycans, and both.
Section snippets
Discovery cohort
The discovery cohort was the DiaGene study. Characteristics of the DiaGene population have been described elsewhere [12]. Briefly, the DiaGene study is a case-control cohort collected in and around the city of Eindhoven, the Netherlands. All hospitals in this area participated, as well as the center for primary care diagnostics. Type 2 diabetes was diagnosed according the ADA and WHO criteria [13], [14]. Patients with other types of diabetes, diabetes secondary to Cushing's syndrome or to
Cohort characteristics
Characteristics of the cohorts are shown in Table 1. In the DiaGene study, patients with type 2 diabetes were more often male (53.7 vs. 40.2% for cases and controls, respectively), had higher BMI and creatinine levels, lower HDL-cholesterol and non-HDL cholesterol levels, and were more often smokers than healthy controls. In the replication cohort, cases were older (66.6 vs. 54.5 years), had a lower HDL-cholesterol, and higher BMI and creatinine.
Clinical traits associated with type 2 diabetes or N-glycosylation
Correlations of clinical traits associated with
Discussion
In the present study, we are the first to describe the association and predictive potential of IgG N-glycans in type 2 diabetes versus healthy individuals in a large case-control study. We have found significant and replicated associations for GP6, GP8, GP9, GP10, and GP11 and several derived IgG glycan traits associated with decreased galactosylation and sialyation, an increase in fucosylated structures with bisecting GlcNAc and a decrease in fucosylated structures without bisecting GlcNAc.
Transparency Document
Acknowledgements
Funding
MH was supported by the Erasmus MC fellowship. Glycan analysis was supported in part by FP7 projects HighGlycan (contract #278535), MIMOmics (contract #305280), MLPM (contract #316861), HTP-GlycoMet (contract #324400) and RegPot Integra-Life (contract #315997) from the European Commission and the HRZZ grant #7769.
Duality of interest
RL, MS, IR, HC, CH, JW, AL, OG, ES, MH declare no conflicts of interest.
FA is a founder and co-owner of Pharmatics Limited. Pharmatics declares no conflicts
References (50)
- et al.
Alternative glycosylation modulates function of IgG and other proteins - implications on evolution and disease
Biochim. Biophys. Acta
(2012) - et al.
The association between galactosylation of immunoglobulin G and body mass index
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2014) - et al.
Runs of homozygosity in European populations
Am. J. Hum. Genet.
(2008) - et al.
Type 2 diabetes: a 21st century epidemic
Best Pract. Res. Clin. Endocrinol. Metab.
(2016) - et al.
Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity
Mol. Immunol.
(2007) - et al.
The role of Fc receptors and complement in autoimmunity
Autoimmun. Rev.
(2013) - et al.
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity
Lancet
(1988) - et al.
N-glycomic biomarkers of biological aging and longevity: a link with inflammaging
Ageing Res. Rev.
(2013) - et al.
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms
J. Biol. Chem.
(2006) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
Cell
(2010)
The complement system in human cardiometabolic disease
Mol. Immunol.
Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis
Biochim. Biophys. Acta
Diabetes mellitus
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes
Nat. Genet.
Complex genetic regulation of protein glycosylation
Mol. BioSyst.
Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis
Diabetes Care
Glycans are a novel biomarker of chronological and biological ages
J. Gerontol. A Biol. Sci. Med. Sci.
Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans
Glycobiology
The association between glycosylation of immunoglobulin G and hypertension: a multiple ethnic cross-sectional study
Medicine (Baltimore)
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Science
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
Science
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
Nat. Genet.
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
Diabet. Med.
Diagnosis and classification of diabetes mellitus
Diabetes Care
Genetic epidemiological studies of eastern Adriatic Island isolates, Croatia: objective and strategies
Coll. Antropol.
Cited by (0)
- 1
These authors contributed equally.